YESCARTA Lead Page

STN: BL 125643Proper Name: axicabtagene ciloleucelTrade Name: YESCARTAManufacturer: Kite Pharma Inc.Indication: YESCARTA is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of:Product InformationSupporting DocumentsJune...

OMUFA Performance Reports

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) (Pub. L. 116-136) was signed into law.  In addition to aiding the COVID-19 response efforts, the CARES Act amended the FD&C Act to include statutory provisions that (1) reform...

ABECMA

STN: BLA 125736Proper Name: Idecabtagene VicleucelTradename: ABECMAManufacturer: Celgene Corporation, a Bristol-Myers Squibb CompanyIndications:Treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including...

CARVYKTI

STN:125746 Proper Name: ciltacabtagene autoleucelTradename: CARVYKTIManufacturer: Janssen Biotech, Inc.Indications: Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy, including a proteasome...

Guidance for Industry

Docket Number: FDA-2013-D-0744 Issued by: Guidance Issuing Office Center for Drug Evaluation and Research, Office of New Drugs The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled “Antibacterial...